Takeaways from the First iDose Open LCD Meeting

Research evidence excerpt

Takeaways from the First iDose Open LCD Meeting

June 9, 2026 Glaukos Corporation

(GKOS, Buy, $162 PT)MEDICAL Ryan Zimmerman

Takeaways from the First iDose Open LCD Meeting (212) 527-3586 rzimmerman@btig.com

Iseult McMahon WHAT YOU SHOULD KNOW: This afternoon, CGS (the Medicare Administrative (332) 400-5103 imcmahon@btig.com

Contractor for Kentucky and Ohio) hosted the first in a series of open meetings Company Data

regarding the proposed LCD for iDose (here). Largely a one-sided discussion, the open

meeting was designed to be a forum for industry and physicians to provide feedback Closing Price $126.34

on the proposed LCD during the ongoing comment period (which closes on July Price Target $162.00

4th). While there were several presentations at today's meeting, we would highlight Market Cap (M) $7,330.50TECHNOLOGY

one speaker who presented on behalf of the American Academy of Ophthalmology, Enterprise Value (M) $8,154.85

the Glaucoma Society, and the American Society of Cataract and Refractive Surgery, Shares Out (M) 58.02

and the Outpatient Ophthalmic Surgery Society. Overall, he highlighted several key Avg Daily Vol-3 Months (M) 0.92

concerns with the proposal including the fact that it is premature given the early

RevisionsEQUITY stage of iDose, step therapy requirements are too restrictive, along with concomitant

procedure and re-administration limitations, among others. As written, the proposal Previous Current

may limit medically necessary clinician flexibility and create unintended patient Rating Buy Buy

access barriers. While these themes (which we discuss in more detail below) were Price Target $162.00 $162.00

consistent among all the speakers, we ultimately believe the society perspective and FY26E REV 632.92 632.92